SelectQuote, Inc. Reports First Quarter of Fiscal Year 2027 Results

SelectQuote, Inc. (SLQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SelectQuote, Inc. Reports First Quarter of Fiscal Year 2027 Results First Quarter of Fiscal Year 2027 – Consolidated Earnings Highlights • Revenue of $280.0 million • Net loss of $(20.3) million • Adjusted EBITDA* of $(17.0) million Fiscal Year 2027 Guidance Ranges:

Event · Earnings
Also in this documentGuidance · reaffirm · $1.35B–$1.45B

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 4, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLQT
Bullish
high confidence
Mentioned
$SLQT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SLQTBullishHigh
01

Why it matters

The guidance narrows the revenue range and projects positive EBITDA, which could shift market expectations.

02

Market read

First‑report earnings and guidance for a mid‑cap health‑tech firm; likely to move the stock in early trading.

03

What to watch

Potential regulatory changes to Medicare Advantage and the Inflation Reduction Act could affect future growth.

Relevance 7/10Novelty 8/10Timing: pre‑market today
AlphAI · Earnings readSLQT · First Quarter of Fiscal Year 2027 · ended September 30, 2026

Revenue declined to $280.0 million, while net loss, Adjusted EBITDA and operating cash flow improved year over year; the company reiterated fiscal year 2027 targets.

→Mixed quarter

Revenue declined across Senior, Healthcare Services and Life, but consolidated net loss narrowed, Adjusted EBITDA improved materially, operating cash use declined, and full-year fiscal 2027 guidance was reiterated.

Revenue
$280M
Senior
$50.8M
(14) % y/y
EPS · GAAP
$ (0.21)
Fiscal Year 2027 outlook
$1.35 billion to $1.45 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30GAAP$280.0M––
Commissions and other services revenue, three months ended September 30GAAP$95.96M––
Pharmacy revenue, three months ended September 30GAAP$184.0M––
Cost of commissions and other services revenue, three months ended September 30GAAP$61.75M––
Cost of goods sold—pharmacy revenue, three months ended September 30GAAP$155.3M––
Marketing and advertising, three months ended September 30GAAP$46.44M––
Selling, general, and administrative, three months ended September 30GAAP$35.91M––
Technical development, three months ended September 30GAAP$9.23M––
Total operating costs and expenses, three months ended September 30GAAP$308.6M––
Loss from operations, three months ended September 30GAAP−$28.59M––
Interest expense, net, three months ended September 30GAAP−$10.97M––
Change in fair value of warrants, three months ended September 30GAAP$12.57M––
Loss before income tax benefit, three months ended September 30GAAP−$26.52M––
Income tax benefit, three months ended September 30GAAP−$6.22M––
Net loss, three months ended September 30GAAP−$20.30M––
Net loss attributable to common shareholders, three months ended September 30GAAP−$40.46M––
Net loss attributable to common shareholders per share, basic, three months ended September 30GAAP$ (0.21)––
Net loss attributable to common shareholders per share, diluted, three months ended September 30GAAP$ (0.21)––
Weighted-average common stock outstanding used in basic per share amounts, three months ended September 30GAAP191.5M––
Weighted-average common stock outstanding used in diluted per share amounts, three months ended September 30GAAP191.5M––
Adjusted EBITDA, three months ended September 30non-GAAP−$17.01M––
Net cash used in operating activities, three months ended September 30GAAP−$17.18M––
Net cash used in investing activities, three months ended September 30GAAP−$3.65M––
Net cash provided by financing activities, three months ended September 30GAAP$13.47M––
Net decrease in cash, cash equivalents and restricted cash, three months ended September 30GAAP−$7.36M––
Cash, cash equivalents, and restricted cash—end of periodGAAP$14.32M––
Senior Adjusted EBITDA Margin, three months ended September 30non-GAAP(24) %––
Healthcare Services Adjusted EBITDA Margin, three months ended September 30non-GAAP6 %––
Life Adjusted EBITDA Margin, three months ended September 30non-GAAP17 %––
Senior Medicare Advantage submitted policies, three months ended September 30other54,459–(22) %
Senior total submitted policies, three months ended September 30other66,494–(24) %
Senior Medicare Advantage approved policies, three months ended September 30other50,976–(18) %
Senior total approved policies, three months ended September 30other59,410–(22) %
Medicare Advantage lifetime value of commissions per approved policy, three months ended September 30other$ 890–16 %
Total SelectRx Members, as of September 30other99,753–decreased by 7%
Profitability per SelectRx member, three months ended September 30non-GAAP$107.6 per member–increased 60%
Prescriptions Per Day, three months ended September 30other28,139––
Combined Senior and Healthcare Services total revenue per MA / MS policy, twelve months ended September 30other2,468–increased 2%
Combined Senior and Healthcare Services total operating expenses per MA / MS policy, twelve months ended September 30other(2,135)–decreased 1%
Combined Senior and Healthcare Services Adjusted EBITDA per MA/MS policy, twelve months ended September 30non-GAAP$ 333––
Combined Senior and Healthcare Services Adjusted EBITDA Margin per MA/MS policy, twelve months ended September 30non-GAAP13 %––
Combined Senior and Healthcare Services Revenue / CAC multiple, twelve months ended September 30other7X––
Life total premiums, three months ended September 30other$38.51M–(21) %

Segments

SegmentRevenueq/qy/y
SeniorMedicare Advantage approved policies were 50,976, down (18) %, while Medicare Advantage lifetime value of commissions per approved policy was $ 890, up 16 %.$50.81M–(14) %
Healthcare ServicesTotal SelectRx Members were 99,753 versus 106,914, with the company citing refined customer qualification focused on long-term profitability and operational efficiency; profitability per SelectRx member increased 60% from $67.1 per member to $107.6 per member.$186.3M–(16) %
LifeTotal premiums were $ 38,507 (in thousands), down (21) %, including Final Expense Premiums of $ 20,059 (in thousands), down (32) %.$42.80M–(8) %

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Fiscal Year 2027 outlook

  • Revenue$1.35 billion to $1.45 billion
  • NoteAdjusted EBITDA* expected in the range of $90 million to $115 million
  • NoteOperating Cash Flow expected to be more than $60 million

What drove it

  • Management cited growing efficiencies, process management, technology- and agent-led service, and AI as contributors to operating leverage.
  • Senior Medicare Advantage lifetime value of commissions per approved policy increased 16 % to $ 890.
  • Healthcare Services Adjusted EBITDA increased 56 % to $ 11,231 (in thousands) despite revenue declining (16) %.
  • The company said the SelectRx member decrease was primarily due to refined customer qualification focused on long-term profitability and operational efficiency.
  • Combined Senior and Healthcare Services total revenue per MA / MS policy increased 2%, while total operating expenses per MA / MS policy decreased 1% for the twelve months ended September 30, 2026.

Concerns

  • Total revenue declined from $ 328,811 (in thousands) to $ 280,007 (in thousands).
  • Senior revenue declined (14) %, Healthcare Services revenue declined (16) %, and Life revenue declined (8) %.
  • Senior total approved policies declined (22) % to 59,410, and total SelectRx Members declined to 99,753 from 106,914.
  • The company reported a net loss of $ (20,301) (in thousands), a loss from operations of $ (28,587) (in thousands), and net cash used in operating activities of $ (17,180) (in thousands).
  • Long-term debt, net—less current portion increased to $ 364,255 (in thousands) from $ 348,154 (in thousands).

What to watch

  • Progress toward fiscal year 2027 revenue of $1.35 billion to $1.45 billion, Adjusted EBITDA of $90 million to $115 million, and operating cash flow of more than $60 million.
  • Medicare Annual Enrollment Period execution and the performance of the tenured agent force.
  • Senior policy volumes and whether higher lifetime value of commissions per approved policy continues to offset lower approved-policy counts.
  • Healthcare Services membership, prescriptions per day, and the durability of profitability per SelectRx member.
  • Operating cash flow and debt levels as the company targets more than $60 million in operating cash flow.

Balance sheet and cash flow

  • Cash, cash equivalents, and restricted cash: $ 13,444 (in thousands) as of September 30, 2026, compared to $ 20,718 (in thousands) as of June 30, 2026.
  • Commissions receivable—Net: $ 805,283 (in thousands) as of September 30, 2026, compared to $ 852,675 (in thousands) as of June 30, 2026.
  • Current portion of long-term debt: $ 21,593 (in thousands) as of September 30, 2026, compared to $ 22,014 (in thousands) as of June 30, 2026.
  • Long-term debt, net—less current portion: $ 364,255 (in thousands) as of September 30, 2026, compared to $ 348,154 (in thousands) as of June 30, 2026.
  • Net cash used in operating activities was $ (17,180) (in thousands), compared to $ (21,623) (in thousands).
  • Purchases of property and equipment were $ (658) (in thousands), and purchases of software and capitalized software development costs were $ (2,989) (in thousands).

Analysis

SelectQuote opened fiscal 2027 with lower revenue but meaningfully improved losses and cash consumption. Total revenue was $ 280,007 (in thousands), compared with $ 328,811 (in thousands) in the prior-year quarter. Net loss narrowed to $ (20,301) (in thousands) from $ (30,459) (in thousands), loss from operations narrowed to $ (28,587) (in thousands) from $ (40,746) (in thousands), and Adjusted EBITDA improved to $ (17,008) (in thousands) from $ (32,079) (in thousands). Net cash used in operating activities improved to $ (17,180) (in thousands) from $ (21,623) (in thousands).

The revenue decline was broad-based. Senior revenue was $ 50,806 (in thousands), down (14) %, with total approved policies down (22) % to 59,410. The Senior segment nevertheless improved Adjusted EBITDA to $ (12,303) (in thousands) from $ (21,036) (in thousands), and its Adjusted EBITDA Margin improved to (24) % from (36) %. Medicare Advantage lifetime value of commissions per approved policy increased 16 % to $ 890, a key offset to lower policy volume.

Healthcare Services remained the largest segment but also faced a revenue decline, reporting $ 186,278 (in thousands), down (16) %. Segment Adjusted EBITDA increased 56 % to $ 11,231 (in thousands), and Adjusted EBITDA Margin increased to 6 % from 3 %. SelectRx membership was 99,753 versus 106,914, and prescriptions per day were 28,139 versus 31,378. Management attributed the membership decline primarily to refined customer qualification, while profitability per SelectRx member increased 60% from $67.1 per member to $107.6 per member.

Life revenue declined (8) % to $ 42,799 (in thousands), while Adjusted EBITDA increased 31 % to $ 7,294 (in thousands) and Adjusted EBITDA Margin increased to 17 % from 12 %. Total Life premiums declined (21) % to $ 38,507 (in thousands), led by a (32) % decline in Final Expense Premiums. Across the combined Senior and Healthcare Services business on a trailing twelve-month basis, total revenue per MA / MS policy increased 2% to 2,468 and total operating expenses per MA / MS policy decreased 1% to (2,135), lifting Adjusted EBITDA per MA/MS policy to $ 333 from $ 284.

The balance sheet showed cash, cash equivalents, and restricted cash of $ 13,444 (in thousands) as of September 30, 2026, while long-term debt, net—less current portion was $ 364,255 (in thousands). The company reiterated fiscal year 2027 guidance for revenue of $1.35 billion to $1.45 billion, Adjusted EBITDA of $90 million to $115 million, and operating cash flow of more than $60 million. The central reporting-period tension is lower revenue and customer or policy volume against improving segment profitability, narrower consolidated losses, and lower operating cash use.

Management, verbatim

We are proud of another strong quarter across both our Senior and Healthcare Services segments, resulting in a material year-over-year improvement in adjusted EBITDA and operating cash flow.

Tim Danker, Chief Executive Officer

We have high confidence in our current and long-term strategy to drive value for stakeholders, and we are pleased to reiterate our full-year financial targets for fiscal 2027.

Tim Danker, Chief Executive Officer

SelectQuote’s performance, in our seasonally slowest quarter, showcases the continued impact of our strategy to optimize profitability and cash flow.

Tim Danker, Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Free cash flow was not reported.
  • No share repurchases or dividends were reported.
  • No previous outlook section was provided, so comparison with prior guidance is unavailable.
  • No forward guidance was reported for gross margin, operating expenses, tax rate, GAAP net income, or GAAP EPS.
  • No prior-quarter figures were reported for the reported quarterly operating metrics.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

SelectQuote filed a Form 8‑K reporting Q1 FY2027 results and FY2027 outlook.

Company-level read

Ticker impact

$SLQTBullishHigh confidence
Context

issued guidance for FY2027 with revenue expected $1.35B‑$1.45B and adjusted EBITDA $90M‑$115M after Q1 loss of $20.3M

Expected impact

likely support as investors price in improved cash flow and issued EBITDA guidance

Evidence & confidence

Guidance issues the outlook from the prior year and exceeds the quarter's loss, which may attract buying pressure.

Market effects

healthcare insurance brokerage sector may see modest upside as SelectQuote's guidance suggests sector‑wide profitability improvement.

U.S. market participants focused on Medicare Advantage space could adjust exposure.

Limited; impact confined to U.S. listed health‑tech stocks.

Counterpoint

Guidance may be overly optimistic given the revenue decline; skeptics could short on execution risk.

Key entities

  • Tim Danker

    CEO of SelectQuote who commented on the results and outlook.

Every SLQT earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$SLQTMed

SelectQuote Inc (SLQT) (Q1 2027) Earnings Call Highlights: Beats EBITDA and Cash Flow

SelectQuote Inc (SLQT) reported Q1 2027 earnings, beating EBITDA and cash flow estimates. President Bob noted stable plan termination and high beneficiary engagement. CFO Ryan Clement highlighted progress toward a $60M operating cash flow target, with potential future cash dividends. CEO Tim Danker mentioned strong front-end production and improved recapture rates. The company is expanding its Olathe facility and investing in technology for other sites.

$SLQTMedAI 8/10

SelectQuote places fewer Medicare policies but earns more on each one

SelectQuote (SLQT) approved 18% fewer Medicare Advantage policies in Q1 2027, with revenue falling to $280M from $329M. However, commission values per policy rose 16% to $890. The company is shrinking its agent force to improve efficiency, and adjusted EBITDA losses narrowed. Healthcare Services revenue fell 16% but adjusted EBITDA rose 56%. SelectQuote maintained its full-year guidance and faces a False Claims Act lawsuit.

$SLQTMed

What SelectQuote (SLQT) Said on Its Q1 Earnings Call

SelectQuote (SLQT) reported Q1 earnings, with Senior revenue declining to $51M from $59M, but adjusted EBITDA loss narrowing. Healthcare Services revenue fell to $186M, while adjusted EBITDA rose 56% to $11M. Life Insurance revenue declined to $43M, but adjusted EBITDA increased 31% to $7M. The company plans a reverse stock split and invests in AI and technology. Management noted stability in commissions and potential carrier marketing efforts.

$SLQTMed

SelectQuote (SLQT) Q1 2027 Earnings Call Transcript

SelectQuote (SLQT) reported a Q1 2027 adjusted EBITDA loss of $17M, improved from last year. Revenue was $280M, down 15% YoY. Senior segment lost $12M (improved $9M YoY), while Healthcare Services EBITDA rose 56% YoY to $11M. The company reiterated its fiscal 2027 operating cash flow target of at least $60M, citing strong profitability and cash flow performance.

$SLQTMedAI 8/10

SelectQuote (SLQT) Q1 2027 Earnings Call Transcript

SelectQuote (SLQT) reported Q1 2027 revenue of $280M, down 15% YoY, with an adjusted EBITDA loss of $17M. Senior revenue fell 14% YoY, while Medicare Advantage policies decreased 18%. Healthcare Services revenue dropped 16%, but EBITDA grew 56%. The company maintained full-year guidance and plans a reverse stock split. Management prioritized profitability over volume, leveraging AI and operational efficiencies.